Strategic Acquisition Cobra Biologics was acquired by Charles River in March 2021, positioning it within a global network of CDMO services and providing opportunities to leverage Charles River's client base for expanded contract manufacturing and development collaborations.

Expanding Capacity Recent growth efforts, including the addition of 50 new positions, indicate capacity expansion which can facilitate larger-scale projects, opening doors for increased contract opportunities in biologics, gene therapy, and viral vector manufacturing.

Industry Recognition Awarded 'Company of the Year' at the Keele Science and Innovation Park, Cobra Biologics demonstrates a reputation for innovation and excellence, making it an attractive partner for pharmaceutical and biotech companies seeking high-quality contract manufacturing solutions.

Strong Industry Links Collaborations with Scancell and partnerships with bioindustry organizations highlight Cobra’s active engagement in vaccine development and immunotherapy fields, presenting opportunities to offer complementary technologies or joint ventures in emerging therapeutic areas.

Growing Market Presence Operating within the competitive biotech space with revenue between $1 million and $10 million and supported by recent acquisitions, Cobra Biologics is poised for market expansion where tailored CDMO services can meet the rising demand for advanced biologics and gene therapies.